Model systems of genetically modified platelets

Blood

Volumn 119, Issue 7, 2012, Pages 1634-1642

  Thijs, Tim ^a   Deckmyn, Hans ^a   Broos, Katleen ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHOLINO OLIGONUCLEOTIDE;

CELL TRANSPLANTATION; EXPERIMENTAL MODEL; GENE PRODUCT; GENETIC ENGINEERING; HEMOSTASIS; HUMAN; IN VIVO STUDY; KNOCKOUT MOUSE; MEGAKARYOCYTE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; STEM CELL; THROMBOCYTE; ZEBRA FISH;

EID: 84857498915     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-381715     Document Type: Review

References (141)

1. Broos K, Feys HB, De Meyer SF, Vanhoorelbeke K, Deckmyn H. Platelets at work in primary hemostasis. Blood Rev. 2011;25(4):155-167.
2. Leslie M. Cell biology: beyond clotting: the powers of platelets. Science. 2010;328(5978):562-564.
3. Nuyttens BP, Thijs T, Deckmyn H, Broos K. Platelet adhesion to collagen. Thromb Res. 2011; 127(suppl 2):S26-S29.
4. Thijs T, Nuyttens BP, Deckmyn H, Broos K. Platelet physiology and antiplatelet agents. Clin Chem Lab Med. 2010;48(suppl 1):S3-S13.
5. Nieswandt B, Pleines I, Bender M. Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke. J Thromb Haemost. 2011;9(suppl 1):92-104.
6. Goodall AH, Burns P, Salles I, et al. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood. 2010;116(22):4646-4656.
7. Meisinger C, Prokisch H, Gieger C, et al. A genome- wide association study identifies three loci associated with mean platelet volume. Am J Hum Genet. 2009;84(1):66-71.
8. Samani NJ, Erdmann J, Hall AS, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007;357(5):443-453. (Pubitemid 47204873)
9. Schunkert H, Konig IR, Kathiresan S, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43(4):333-338.
10. Soranzo N, Spector TD, Mangino M, et al. A genome- wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet. 2009;41(11): 1182-1190.
11. Soranzo N, Rendon A, Gieger C, et al. A novel variant on chromosome 7q22.3 associated with mean platelet volume, counts, and function. Blood. 2009;113(16):3831-3837.
12. Gnatenko DV, Dunn JJ, McCorkle SR, et al. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood. 2003;101(6):2285-2293. (Pubitemid 36302071)
13. Jones CI, Bray S, Garner SF, et al. A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathways. Blood. 2009;114(7):1405-1416.
14. McRedmond JP, Park SD, Reilly DF, et al. Integration of proteomics and genomics in platelets: a profile of platelet proteins and platelet-specific genes. Mol Cell Proteomics. 2004;3(2):133-144. (Pubitemid 38714271)
15. Senis YA, Tomlinson MG, Garcia A, et al. A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein. Mol Cell Proteomics. 2007;6(3):548-564. (Pubitemid 46554548)
16. Macaulay IC, Tijssen MR, Thijssen-Timmer DC, et al. Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood. 2007;109(8): 3260-3269. (Pubitemid 46572511)
17. O'Connor MN, Salles II, Cvejic A, et al. Functional genomics in zebrafish permits rapid characterization of novel platelet membrane proteins. Blood. 2009;113(19):4754-4762.
18. Jurak Begonja A, Hoffmeister KM, Hartwig JH, Falet H. FlnA-null megakaryocytes prematurely release large and fragile platelets that circulate poorly. Blood. 2011;118(8):2285-2295.
19. Rowley JW, Oler AJ, Tolley ND, et al. Genomewide RNA-seq analysis of human and mouse platelet transcriptomes. Blood. 2011;118(14): e101-e111.
20. Zufferey A, Fontana P, Reny JL, Nolli S, Sanchez JC. Platelet proteomics [published online ahead of print October 18, 2011]. Mass Spectrom Rev. doi: 10.1002/mas.20345.
21. Dittrich M, Birschmann I, Mietner S, et al. Platelet protein interactions: map, signaling components, and phosphorylation groundstate. Arterioscler Thromb Vasc Biol. 2008;28(7):1326-1331.
22. .Watkins NA, Gusnanto A, de Bono B, et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood. 2009; 113(19):e1-e9.
23. Albers CA, Cvejic A, Favier R, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43(8):735-737.
24. Feng D, Crane K, Rozenvayn N, Dvorak AM, Flaumenhaft R. Subcellular distribution of 3 functional platelet SNARE proteins: human cellubrevin, SNAP-23, and syntaxin 2. Blood. 2002; 99(11):4006-4014. (Pubitemid 35332041)
25. Polgár J, Chung SH, Reed GL. Vesicle-associated membrane protein 3 (VAMP-3) and VAMP-8 are present in human platelets and are required for granule secretion. Blood. 2002;100(3):1081-1083. (Pubitemid 34832645)
26. Schraw TD, Rutledge TW, Crawford GL, et al. Granule stores from cellubrevin/VAMP-3 null mouse platelets exhibit normal stimulus-induced release. Blood. 2003;102(5):1716-1722. (Pubitemid 37022565)
27. Jagadeeswaran P, Sheehan JP, Craig FE, Troyer D. Identification and characterization of zebrafish thrombocytes. Br J Haematol. 1999;107(4):731-738. (Pubitemid 30020143)
28. Jagadeeswaran P, Lin S, Weinstein B, Hutson A, Kim S. Loss of GATA1 and gain of FLI1 expression during thrombocyte maturation. Blood Cells Mol Dis. 2010;44(3):175-180.
29. Gregory M, Hanumanthaiah R, Jagadeeswaran P. Genetic analysis of hemostasis and thrombosis using vascular occlusion. Blood Cells Mol Dis. 2002;29(3):286-295.
30. Jagadeeswaran P. Zebrafish: a tool to study hemostasis and thrombosis. Curr Opin Hematol. 2005;12(2):149-152. (Pubitemid 40315700)
31. Lang MR, Gihr G, Gawaz MP, Muller II. Hemostasis in Danio rerio: is the zebrafish a useful model for platelet research? J Thromb Haemost. 2010; 8(6):1159-1169.
32. Carrillo M, Kim S, Rajpurohit SK, Kulkarni V, Jagadeeswaran P. Zebrafish von Willebrand factor. Blood Cells Mol Dis. 2010;45(4):326-333.
33. Grosser T, Yusuff S, Cheskis E, Pack MA, FitzGerald GA. Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A. 2002;99(12):8418-8423. (Pubitemid 34651067)
34. Kim S, Carrillo M, Kulkarni V, Jagadeeswaran P. Evolution of primary hemostasis in early vertebrates. PLoS One. 2009;4(12):e8403.
35. Lin HF, Traver D, Zhu H, et al. Analysis of thrombocyte development in CD41-GFP transgenic zebrafish. Blood. 2005;106(12):3803-3810. (Pubitemid 41739016)
36. Salles II, O'Connor MN, Thijssen-Timmer DC, Broos K, Deckmyn H. Platelet functional genomics. In: Garcia A, Senis YA, eds. Platelet Proteomics: Principles, Analysis and Applications. New York, NY: Wiley & Sons; 2011.
37. Flicek P, Amode MR, Barrell D, et al. Ensembl 2011. Nucleic Acids Res. 2011;39(Database issue): D800-D806.
38. Bolli N, Payne EM, Rhodes J, et al. cpsf1 is required for definitive HSC survival in zebrafish. Blood. 2011;117(15):3996-4007.
39. Johnson HJ, Gandhi MJ, Shafizadeh E, et al. In vivo inactivation of MASTL kinase results in thrombocytopenia. Exp Hematol. 2009;37(8):901- 908.
40. Ma D, Zhang J, Lin HF, Italiano J, Handin RI. The identification and characterization of zebrafish hematopoietic stem cells. Blood. 2011;118(2): 289-297.
41. Driever W, Fishman MC. The zebrafish: heritable disorders in transparent embryos. J Clin Invest. 1996;97(8):1788-1794. (Pubitemid 26129864)
42. Morcos PA, Li Y, Jiang S. Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques. 2008;45(6):613-614.
43. Nasevicius A, Ekker SC. Effective targeted gene 'knockdown' in zebrafish. Nat Genet. 2000;26(2): 216-220.
44. Bahadori R, Rinner O, Schonthaler HB, et al. The Zebrafish fade out mutant: a novel genetic model for Hermansky-Pudlak syndrome. Invest Ophthalmol Vis Sci. 2006;47(10):4523-4531. (Pubitemid 46579381)
45. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet alpha-granules. Nat Genet. 2011;43(8):732-734.
46. Kahr WH, Hinckley J, Li L, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet. 2011;43(8):738- 740.
47. Drachman JG, Jarvik GP, Mehaffey MG. Autosomal dominant thrombocytopenia: incomplete megakaryocyte differentiation and linkage to human chromosome 10. Blood. 2000;96(1):118- 125.
48. Savoia A, Del VM, Totaro A, et al. An autosomal dominant thrombocytopenia gene maps to chromosomal region 10p. Am J Hum Genet. 1999; 65(5):1401-1405. (Pubitemid 30460391)
49. Stalker TJ, Wu J, Morgans A, et al. Endothelial cell specific adhesion molecule (ESAM) localizes to platelet-platelet contacts and regulates thrombus formation in vivo. J Thromb Haemost. 2009; 7(11):1886-1896.
50. Kim S, Radhakrishnan UP, Rajpurohit SK, Kulkarni V, Jagadeeswaran P. Vivo-Morpholino knockdown of alphaIIb: a novel approach to inhibit thrombocyte function in adult zebrafish. Blood Cells Mol Dis. 2010;44(3):169-174.
51. Konopatskaya O, Matthews SA, Harper MT, et al. Protein kinase C mediates platelet secretion and thrombus formation through protein kinase D2. Blood. 2011;118(2):416-424.
52. Signarvic RS, Cierniewska A, Stalker TJ, et al. RGS/Gi2alpha interactions modulate platelet accumulation and thrombus formation at sites of vascular injury. Blood. 2010;116(26):6092-6100.
53. Whinna HC. Overview of murine thrombosis models. Thromb Res. 2008;122(suppl 1):S64-S69.
54. Braun A, Varga-Szabo D, Kleinschnitz C, et al. Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation. Blood. 2009;113(9):2056-2063.
55. Crittenden JR, Bergmeier W, Zhang Y, et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med. 2004;10(9):982-986. (Pubitemid 39273740)
56. Hodivala-Dilke KM, McHugh KP, Tsakiris DA, et al. Beta3-integrin- deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. J Clin Invest. 1999; 103(2):229-238. (Pubitemid 29053141)
57. Li D, D'Angelo L, Chavez M, Woulfe DS. Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets. J Biol Chem. 2011; 286(5):3805-3814.
58. Moser M, Nieswandt B, Ussar S, Pozgajova M, Fassler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med. 2008; 14(3):325-330. (Pubitemid 351347914)
59. Kanaji T, Russell S, Cunningham J, et al. Mega-karyocyte proliferation and ploidy regulated by the cytoplasmic tail of glycoprotein Ibalpha. Blood. 2004;104(10):3161-3168. (Pubitemid 39507130)
60. Poujol C, Ware J, Nieswandt B, Nurden AT, Nurden P. Absence of GPIbalpha is responsible for aberrant membrane development during megakaryocyte maturation: ultrastructural study using a transgenic model. Exp Hematol. 2002; 30(4):352-360. (Pubitemid 34286441)
61. Strassel C, Nonne C, Eckly A, et al. Decreased thrombotic tendency in mouse models of the Bernard-Soulier syndrome. Arterioscler Thromb Vasc Biol. 2007;27(1):241-247. (Pubitemid 46360405)
62. Strassel C, Eckly A, Leon C, et al. Intrinsic impaired proplatelet formation and microtubule coil assembly of megakaryocytes in a mouse model of Bernard-Soulier syndrome. Haematologica. 2009;94(6):800-810.
63. .Ware J, Russell S, Ruggeri ZM. Generation and rescue of a murine model of platelet dysfunction: the Bernard-Soulier syndrome. Proc Natl Acad Sci U S A. 2000;97(6):2803-2808. (Pubitemid 30159252)
64. Poujol C, Ramakrishnan V, DeGuzman F, et al. Ultrastructural analysis of megakaryocytes in GPV knockout mice. Thromb Haemost. 2000; 84(2):312-318. (Pubitemid 30601480)
65. Kanaji S, Kuether EL, Fahs SA, et al. Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy [published online ahead of print, November 1, 2011]. Mol Ther. doi: 10.1038/mt.2011.231.
66. Hart AW, Morgan JE, Schneider J, et al. Cardiac malformations and midline skeletal defects in mice lacking filamin A. Hum Mol Genet. 2006; 15(16):2457-2467. (Pubitemid 44288699)
67. Monkley SJ, Zhou XH, Kinston SJ, et al. Disruption of the talin gene arrests mouse development at the gastrulation stage. Dev Dyn. 2000;219(4): 560-574.
68. Suzuki-Inoue K, Inoue O, Ding G, et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem. 2010;285(32):24494- 24507.
69. Kühn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995; 269(5229):1427-1429.
70. Hall MA, Curtis DJ, Metcalf D, et al. The critical regulator of embryonic hematopoiesis, SCL, is vital in the adult for megakaryopoiesis, erythropoiesis, and lineage choice in CFU-S12. Proc Natl Acad Sci U S A. 2003;100(3):992-997. (Pubitemid 36183943)
71. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10(3):299-304. (Pubitemid 38667622)
72. Nowakowski A, Alonso-Martin S, Arias-Salgado EG, et al. Megakaryocyte gene targeting mediated by restricted expression of recombinase Cre. Thromb Haemost. 2011;105(1):138-144.
73. Tiedt R, Schomber T, Hao-Shen H, Skoda RC. Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo. Blood. 2007;109(4):1503-1506. (Pubitemid 46239582)
74. Jasinski M, Keller P, Fujiwara Y, Orkin SH, Bessler M. GATA1-Cre mediates Piga gene inactivation in the erythroid/megakaryocytic lineage and leads to circulating red cells with a partial deficiency in glycosyl phosphatidylinositol-linked proteins (paroxysmal nocturnal hemoglobinuria type II cells). Blood. 2001;98(7):2248-2255.
75. Tiedt R, Hao-Shen H, Sobas MA, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111(8):3931-3940.
76. Bhavaraju K, Lakhani PR, Dorsam RT, et al. G(12/13) signaling pathways substitute for integrin alphaIIbbeta3-signaling for thromboxane generation in platelets. PLoS One. 2011;6(2):e16586.
77. Mitsios JV, Prevost N, Kasirer-Friede A, et al. What is vinculin needed for in platelets? J Thromb Haemost. 2010;8(10):2294-2304.
78. Petrich BG, Marchese P, Ruggeri ZM, et al. Talin is required for integrin-mediated platelet function in hemostasis and thrombosis. J Exp Med. 2007; 204(13):3103-3111.
79. .Wen Q, Leung C, Huang Z, et al. Survivin is not required for the endomitotic cell cycle of mega-karyocytes. Blood. 2009;114(1):153-156.
80. Ahmad F, Boulaftali Y, Greene TK, et al. Relative contributions of stromal interaction molecule 1 and CalDAG-GEFI to calcium-dependent platelet activation and thrombosis. J Thromb Haemost. 2011;9(10):2077-2086.
81. Thyagarajan B, Guimaraes MJ, Groth AC, Calos MP. Mammalian genomes contain active recombinase recognition sites. Gene. 2000; 244(1-2):47-54. (Pubitemid 30109559)
82. Lepage A, Leboeuf M, Cazenave JP, et al. The alpha(IIb)beta(3) integrin and GPIb-V-IX complex identify distinct stages in the maturation of CD34(+) cord blood cells to megakaryocytes. Blood. 2000;96(13):4169-4177.
83. Szalai G, LaRue AC, Watson DK. Molecular mechanisms of megakaryopoiesis. Cell Mol Life Sci. 2006;63(21):2460-2476. (Pubitemid 44722378)
84. Falet H, Pollitt AY, Begonja AJ, et al. A novel interaction between FlnA and Syk regulates platelet ITAM-mediated receptor signaling and function. J Exp Med. 2010;207(9):1967-1979.
85. Prandini MH, Uzan G, Martin F, Thevenon D, Marguerie G. Characterization of a specific erythromegakaryocytic enhancer within the glycoprotein IIb promoter. J Biol Chem. 1992;267(15): 10370-10374.
86. Denis CV, Wagner DD. Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol. 2007;27(4): 728-739. (Pubitemid 46606699)
87. Motto DG, Chauhan AK, Zhu G, et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest. 2005;115(10):2752-2761. (Pubitemid 41434402)
88. Salmon P, Kindler V, Ducrey O, et al. High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors. Blood. 2000;96(10):3392-3398.
89. .Wu MH, Smith SL, Dolan ME. High efficiency electroporation of human umbilical cord blood CD34+ hematopoietic precursor cells. Stem Cells. 2001;19(6):492-499. (Pubitemid 33095844)
90. Fang J, Hodivala-Dilke K, Johnson BD, et al. Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. Blood. 2005;106(8): 2671-2679. (Pubitemid 41510739)
91. Gao Z, Golob J, Tanavde VM, et al. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector. Stem Cells. 2001; 19(3):247-259. (Pubitemid 32524545)
92. Heckl D, Wicke DC, Brugman MH, et al. Lentiviral gene transfer regenerates hematopoietic stem cells in a mouse model for Mpl-deficient aplastic anemia. Blood. 2011;117(14):3737-3747.
93. Lavenu-Bombled C, Izac B, Legrand F, et al. Glycoprotein Ibalpha promoter drives megakaryocytic lineage-restricted expression after hematopoietic stem cell transduction using a selfinactivating lentiviral vector. Stem Cells. 2007; 25(6):1571-1577. (Pubitemid 47106027)
94. Ohmori T, Kashiwakura Y, Ishiwata A, et al. Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence. Arterioscler Thromb Vasc Biol. 2007;27(10):2266-2272. (Pubitemid 350287259)
95. Piacibello W, Bruno S, Sanavio F, et al. Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice: nonobese diabetic/severe combined immunodeficient. Blood. 2002;100(13): 4391-4400. (Pubitemid 35429677)
96. Shi Q, Wilcox DA, Morateck PA, et al. Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. J Thromb Haemost. 2004;2(11):1989-1997. (Pubitemid 40192753)
97. Tesio M, Gammaitoni L, Gunetti M, et al. Sustained long-term engraftment and transgene expression of peripheral blood CD34+ cells transduced with third-generation lentiviral vectors. Stem Cells. 2008;26(6):1620-1627.
98. .Woods NB, Fahlman C, Mikkola H, et al. Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. Blood. 2000; 96(12):3725-3733.
99. Sinn PL, Sauter SL, McCray PB Jr. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors - design, biosafety, and production. Gene Ther. 2005; 12(14):1089-1098. (Pubitemid 41030614)
100. Woods NB, Muessig A, Schmidt M, et al. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Blood. 2003;101(4):1284-1289. (Pubitemid 36182497)
101. Varma NR, Janic B, Ali MM, Iskander A, Arbab AS. Lentiviral based gene transduction and promoter studies in human hematopoietic stem cells (hHSCs). J Stem Cells Regen Med. 2011;7(1):41- 53.
102. Cocault L, Bouscary D, Le Bousse KC, et al. Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation. Blood. 1996;88(5):1656-1665. (Pubitemid 26307060)
103. Heidenreich R, Eisman R, Surrey S, et al. Organization of the gene for platelet glycoprotein IIb. Biochemistry. 1990;29(5):1232-1244. (Pubitemid 20053847)
104. Wilcox DA, Olsen JC, Ishizawa L, Griffith M, White GC. Integrin alphaIIb promoter-targeted expression of gene products in megakaryocytes derived from retrovirus-transduced human hematopoietic cells. Proc Natl Acad Sci U S A. 1999; 96(17):9654-9659. (Pubitemid 29398787)
105. Greene TK, Wang C, Hirsch JD, et al. In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood. 2010;116(26):6114- 6122.
106. Ohmori T, Mimuro J, Takano K, et al. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy. FASEB J. 2006; 20(9):1522-1524.
107. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell. 2006;124(6):1283-1298.
108. Shi Q, Wilcox DA, Fahs SA, et al. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost. 2007;5(2):352-361. (Pubitemid 46139461)
109. Shi Q, Wilcox DA, Fahs SA, et al. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest. 2006;116(7):1974-1982. (Pubitemid 44033321)
110. Shi Q, Fahs SA, Wilcox DA, et al. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood. 2008;112(7):2713-2721.
111. Wilcox DA, Olsen JC, Ishizawa L, et al. Megakaryocyte-targeted synthesis of the integrin beta(3)-subunit results in the phenotypic correction of Glanzmann thrombasthenia. Blood. 2000; 95(12):3645-3651.
112. Fang J, Jensen ES, Boudreaux MK, et al. Platelet gene therapy improves hemostatic function for integrin alphaIIbbeta3-deficient dogs. Proc Natl Acad Sci U S A. 2011;108(23):9583-9588.
113. Peeters K, Loyen S, Van KS, et al. Thrombopoietic effect of VPAC1 inhibition during megakaryopoiesis. Br J Haematol. 2010;151(1):54-61.
114. Zhang G, Shi Q, Fahs SA, et al. Factor IX ectopically expressed in platelets can be stored in alpha- granules and corrects the phenotype of hemophilia B mice. Blood. 2010;116(8):1235-1243.
115. Urnov FD, Rebar EJ, Holmes MC, Zhang HS, Gregory PD. Genome editing with engineered zinc finger nucleases. Nat Rev Genet. 2010; 11(9):636-646.
116. Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol. 2011;29(8):731- 734.
117. Miller JC, Tan S, Qiao G, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol. 2011;29(2):143-148.
118. Sander JD, Cade L, Khayter C, et al. Targeted gene disruption in somatic zebrafish cells using engineered TALENs. Nat Biotechnol. 2011;29(8): 697-698.
119. Tesson L, Usal C, Menoret S, et al. Knockout rats generated by embryo microinjection of TALENs. Nat Biotechnol. 2011;29(8):695-696.
120. Amendola M, Passerini L, Pucci F, et al. Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther. 2009;17(6):1039-1052.
121. Figueiredo C, Goudeva L, Horn PA, et al. Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion. 2010;50(8): 1690-1701.
122. Hong W, Kondkar AA, Nagalla S, et al. Transfection of human platelets with short interfering RNA. Clin Transl Sci. 2011;4(3):180-182.
123. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A. 2005;102(37):13212-13217. (Pubitemid 41325003)
124. Scherr M, Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle. 2007;6(4):444-449. (Pubitemid 46393448)
125. Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet. 2004;5(5): 355-365. (Pubitemid 38529407)
126. Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods. 2006;3(9): 670-676. (Pubitemid 44275732)
127. Bauer M, Kinkl N, Meixner A, et al. Prevention of interferon-stimulated gene expression using microRNA-designed hairpins. Gene Ther. 2009; 16(1):142-147.
128. Beer S, Bellovin DI, Lee JS, et al. Low-level shRNA cytotoxicity can contribute to MYC-induced hepatocellular carcinoma in adult mice. Mol Ther. 2010;18(1):161-170.
129. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther. 2009;17(1):169-175.
130. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/ short hairpin RNA pathways. Nature. 2006; 441(7092):537-541. (Pubitemid 44050158)
131. Nielsen TT, Marion I, Hasholt L, Lundberg C. Neuron-specific RNA interference using lentiviral vectors. J Gene Med. 2009;11(7):559-569.
132. Yang W, Paschen W. Conditional gene silencing in mammalian cells mediated by a stress-inducible promoter. Biochem Biophys Res Commun. 2008;365(3):521-527. (Pubitemid 350181692)
133. Jang JH, Schaffer DV, Shea LD. Engineering biomaterial systems to enhance viral vector gene delivery. Mol Ther. 2011;19(8):1407-1415.
134. Mátrai J, Chuah MK, Vanden Driessche T. Recent advances in lentiviral vector development and applications. Mol Ther. 2010;18(3):477-490.
135. Mátés L, Chuah MK, Belay E, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009;41(6):753-761.
136. Sumiyoshi T, Holt NG, Hollis RP, et al. Stable transgene expression in primitive human CD34+hematopoietic stem/progenitor cells, using the Sleeping Beauty transposon system. Hum Gene Ther. 2009;20(12):1607-1626.
137. Xue X, Huang X, Nodland SE, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood. 2009;114(7):1319-1330.
138. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol. 2007;7(2):118-130. (Pubitemid 46174859)
139. Salles II, Thijs T, Brunaud C, et al. Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34(+) cells are functionally active in an ex vivo flow model of thrombosis. Blood. 2009;114(24):5044- 5051.
140. Tijssen MR, van Hennik PB, di Summa F, et al. Transplantation of human peripheral blood CD34- positive cells in combination with ex vivo generated megakaryocytes results in fast platelet formation in NOD/SCID mice. Leukemia. 2008; 22(1):203-208.
141. McDermott SP, Eppert K, Lechman ER, Doedens M, Dick JE. Comparison of human cord blood engraftment between immunocompromised mouse strains. Blood. 2010;116(2):193-200.